In a phase 3b trial of adults with type 2 diabetes and obesity, a higher 7.2 mg maintenance dose of once‑weekly semaglutide achieved greater reductions in HbA1c and body weight than standard lower doses, with similar overall safety. More participants reached composite glycemic and weight targets, and gastrointestinal events remained the main tolerability issue, generally manageable and non‑serious. The findings expand dose‑optimization options for patients needing more intensive metabolic control. To Read more Click Here ##Reference## Lingvay I, et al. Once‑weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomized, controlled, phase 3b trial.
Lancet Diabetes Endocrinol. 2025;13(11):935‑948. doi:10.1016/S2213-8587(25)00225-6.## In your experience, what is the main consideration when escalating GLP‑1RA doses in T2D with obesity? a) Balancing…
